Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AFT PharmaceuticalsASX:AFP +1.92%90 EV-to-EBIT is 18.28 as of Jul. 14, 2026, which is 7% below its 10-year median of 19.63. GuruFocus rates ASX:AFP with a GF Score™ of 90/100 and a GF Value™ of A$3.39 (Fairly Valued). The stock has 4 warning signs investors should review. Among 688 Drug Manufacturers companies, AFT Pharmaceuticals ranks worse than 56.4% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AFT Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was A$321.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$20.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals EV-to-EBIT Related Terms
AFT Pharmaceuticals EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's EV-to-EBIT falls into.
AFT Pharmaceuticals's current Enterprise Value is A$373.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AFT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$20.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFT Pharmaceuticals (ASX:AFP) has a EV-to-EBIT of 18.28 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AFT Pharmaceuticals and its competitors. This is near median its historical median of 19.63. According to the industry distribution chart, AFT Pharmaceuticals ranks #388 out of 688 companies in the Drug Manufacturers industry, placing it in the top 56.4%.
Is AFT Pharmaceuticals' EV-to-EBIT too high?
AFT Pharmaceuticals' current EV-to-EBIT of 18.28 is near median its 10-year median of 19.63. The Drug Manufacturers industry median EV-to-EBIT is 15.89. AFT Pharmaceuticals' value of 18.28 is 15.1% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #388 out of 688 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #388 out of 688 companies for EV-to-EBIT. This places AFT Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.89. AFT Pharmaceuticals' value of 18.28 is 15.1% above this benchmark. While the company's 10-year median is 19.63 vs. the industry median of 15.89, AFT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.89, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current EV-to-EBIT of 18.28 is 15.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current EV-to-EBIT is 18.28, which is near median its own 10-year median of 19.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current EV-to-EBIT is 18.28, which is near median its 10-year median of 19.63 and 15.1% above the Drug Manufacturers industry median of 15.89. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current EV-to-EBIT is 18.28 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for ASX:AFP:
EV-to-EBIT: 18.28 (near median its 10-year median of 19.63)
GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
Industry Position: 15.1% above the Drug Manufacturers median (#388 of 688)
No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score
Get the complete analysis for ASX:AFP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AFP has been successfully added to your 
